Merck's Experimental Eye Drug Shows Promise Amid Safety Concerns, Ticker MRK
Merck's Experimental Eye Drug Shows Promise Amid Safety Concerns, Ticker MRK GuruFocus
Covered in this story
Analyst targets on Merck & Co.
- Cantor Fitzgerald: $142 → $145 by Oct 2027 · Neutral via MarketBeat
- Morgan Stanley: $143 → $177 by Oct 2027 · Overweight via MarketBeat
- JPMorgan: $140 → $165 by Oct 2027 · Overweight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 31 stories mentioning Merck & Co., the earliest published 26 Jun 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.